Aplastic Anemia Market Report 2024

The aplastic anemia market size has grown strongly in recent years. It will grow from $6.26 billion in 2023 to $6.63 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. In the historic period, growth can be linked to an uptick in blood disorders prevalence, heightened awareness of aplastic anemia and related conditions, increased efforts by both public and private sectors, growing demand for targeted treatments, and rising incidence of bone marrow diseases.

The aplastic anemia market size is expected to see strong growth in the next few years. It will grow to $8.36 billion in 2028 at a compound annual growth rate (CAGR) of 6%. Looking ahead to the forecast period, growth is expected due to higher prevalence rates among elderly populations, supportive regulatory frameworks for drug development, advocacy efforts and support networks for patients, comprehensive epidemiological research, and enhanced awareness and diagnostic capabilities. Key trends in this period include advancements in gene-editing technologies, expansion of telemedicine and remote monitoring, development of biomarkers, adoption of biologics and monoclonal antibodies, and the emergence of patient-specific therapies.

The growth of the aplastic anemia market is anticipated to be driven by increasing healthcare expenditure. This trend is supported by factors such as aging populations and rising incidence of chronic diseases that necessitate expensive treatments. Healthcare spending facilitates aplastic anemia treatment by funding specialized medical facilities, advanced therapies, and research for effective treatments. For example, in May 2023, the United Kingdom spent $356.39 billion (£280.7 billion) on healthcare in 2021, amounting to $5318 (£4,188) per person, representing 12.4% of GDP, slightly up from the previous year. Government-funded healthcare spending rose by 9.6% in real terms, constituting 83% of total healthcare expenditure. Consequently, increasing healthcare expenditure is propelling growth in the aplastic anemia market.

The growth of the aplastic anemia market is expected to be driven by the rising demand for personalized medicines. Personalized medicine involves tailoring medical treatments to individual patient characteristics, often based on genetic or molecular profiling. This demand is fueled by advancements in genetic testing and molecular diagnostics. Personalized medicine in aplastic anemia entails customized treatments based on genetic and molecular profiles to optimize patient outcomes. For instance, in February 2024, the FDA approved 16 novel personalized therapies for rare diseases in 2023, compared to six in 2022, according to the Personalized Medicine Coalition, a US-based non-profit organization. Hence, the increasing demand for personalized medicines is fostering growth in the aplastic anemia market.

Leading companies in the aplastic anemia market are adopting strategic partnerships to enhance research, expand treatment options, and improve patient outcomes. Strategic partnerships involve leveraging mutual strengths and resources for mutual benefits and success. For example, in February 2022, Hemanext Inc., a US-based biomedical technology company, partnered with The Aplastic Anemia and MDS International Foundation (AAMDS), a US-based nonprofit health organization. This collaboration aims to support patients with aplastic anemia, myelodysplastic syndrome (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. Through this partnership, Hemanext will advance its mission of providing support, answers, and hope to thousands of patients and families affected by bone marrow failure diseases.

Major companies operating in the aplastic anemia market are Pfizer Inc., Johnson & Johnson Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceuticals Co. Ltd., UCB SA, Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Cadila Healthcare Limited, Cellenkos Inc., Amyndas Pharmaceuticals S.A., Hemogenyx Pharmaceuticals plc, Gamida Cell Ltd.

North America was the largest region in the aplastic anemia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aplastic anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the aplastic anemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Aplastic anemia is a rare disorder characterized by insufficient production of blood cells red blood cells, white blood cells, and platelets by the bone marrow. This deficiency can result in symptoms such as fatigue, susceptibility to infections, and increased risk of bleeding or bruising. Treatment options range from medications aimed at stimulating blood cell production to potentially requiring bone marrow transplantation in severe cases.

There are two primary types of aplastic anemia acquired aplastic anemia and inherited bone marrow failure syndromes. Acquired aplastic anemia occurs when the bone marrow fails to generate enough blood cells due to damage caused by external factors such as chemicals, medications, or infections. Treatment modalities include bone marrow or stem cell transplantation, blood transfusions, and drug therapies administered via various routes such as oral or parenteral. These treatments are distributed through channels including hospital pharmacies, retail pharmacies, and online platforms, catering to end users such as hospitals, home care settings, specialty clinics, and others.

The aplastic anemia research report is one of a series of new reports that provides aplastic anemia market statistics, including the aplastic anemia industry's global market size, regional shares, competitors with an aplastic anemia market share, detailed aplastic anemia market segments, market trends and opportunities, and any further data you may need to thrive in the aplastic anemia industry. This aplastic anemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The aplastic anemia market consists of revenues earned by entities by providing services such as supportive care for infections and monitoring and management of complications. The market value includes the value of related goods sold by the service provider or included within the service offering. The aplastic anemia market also includes sales of immunosuppressive medications and antibiotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.